Biotech Values

[mskatiescarletohara]

Bravo Dew.

I wonder how REGN is progressing with VEGF-Trap right now for ocular, and in the cancer indications they started out at .5 mg. I think the FDA is scrutinizing angiogenic drugs these days thanks to Avastin, and other data from EYET as you have pointed out. PPHM's IND for Tarvacin had been planned to dose 1mg, and the FDA will not allow it until they get further data from the company. It appears they can't enroll until they supply information relating to dosing .5mg. The kicker is, is they have primate data to support the 1mg dosing and there are no toxicities, they dosed the primates up to 100 mg before toxicities began to show.

The FDA needs a leader and perhaps some angiogenesis drug activists. It's tough being one of the 'first' guys to develop them.

katie...